Business Summary
Vertex Pharmaceuticals is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases in specialty markets. The company generates revenue primarily through product sales of approved medicines for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and acute pain, sold through specialty pharmacies, specialty distributors, and government-owned hospitals worldwide. Its customers are patients with rare and serious diseases whose care is largely managed through specialty healthcare providers and reimbursed by government and commercial payers across more than 60 countries.
Products & Services
Approved Products — Cystic Fibrosis (CFTR Modulators) - ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Most recently approved triple combination; once-daily dosing; approved 2024 for ages 6+ - TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor) — Flagship triple combination; approved 2019 for ages 2+; most widely used - SYMDEKO/SYMKEVI (tezacaftor/ivacaftor) — Dual combination; approved 2018 for ages 6+ - ORKAMBI (lumacaftor/ivacaftor) — Dual combination; approved 2015...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 13, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| Capital World Investors | $13.0B |
| BlackRock Inc | $12.0B |
| Capital Research Global Investors | $9.7B |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.2B |
| STATE STREET CORPORATION | $5.9B |
Annual results · 10-K
Fiscal 2025- Revenue
- $12.0B
- Net income
- $4.0B
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
Securities
| CUSIP | Security | Type |
|---|---|---|
| 92532F100 | VRTX VERTEX PHARMACEUTICALS INC | Common stock |
| 92532FAA8 | VRTX VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAN0 | VRTX 3.35 10/01/15 VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAM2 | VRTX 4.75 02/15/13 VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAB6 | VRTX 5 03/14/07 VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAC4 | VRTX 5 09/19/07 144A VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAD2 | VRTX 5 09/19/07 REGS VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAK6 | VRTX 5.75 02/15/11 VERTEX PHARMACEUTICALS INC | Bond |
| 92532FAF7 | VRTX 5.75 02/15/11 * VERTEX PHARMACEUTICALS INC | Bond |
Insider trades · Form 4
Latest filings
- Daniel J. Brennan 2026-10-22 Award
- Bruce I Sachs 2026-10-19 Award
- Alan M Garber 2026-10-19 Award
- Grunsven Jasper Van 2026-09-10 Award
- Kristen Ambrose 2026-09-01 Award
5%+ holders · 13D/G
3 filers| Filer | % of class | Filed |
|---|---|---|
| Capital Research Global Investors 13G | 8.3% | 2026-05-14 |
| Capital World Investors 13G | 10.1% | 2026-05-14 |
| VANGUARD CAPITAL MANAGEMENT LLC 13G | 7.5% | 2026-04-30 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.